{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166122806",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166122806",
  "name" : "CPIC Dosing Guideline for phenytoin and CYP2C9,HLA-B",
  "guides" : [ {
    "locus" : "HLA-B",
    "locusId" : "PA35056",
    "alleles" : [ "*15:02:01", "other" ],
    "anns" : [ {
      "id" : 1184754194,
      "drug" : {
        "objCls" : "Drug",
        "@id" : "https://www.pharmgkb.org/data/drug/PA450947",
        "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
        "id" : "PA450947",
        "name" : "phenytoin"
      },
      "groups" : [ {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      } ],
      "strength" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501929,
        "src" : "guidelineStrength",
        "term" : "N/A",
        "termId" : "guidelineStrength:981501929"
      },
      "textHtml" : "<p>Homozygous for an allele other than HLA-B:*15:02; at “normal” or reduced risk of phenytoin-associated cutaneous adverse reactions</p>"
    }, {
      "id" : 1184754184,
      "diplotypeIds1" : [ "PA165954769" ],
      "diplotypeIds2" : [ null ],
      "drug" : {
        "objCls" : "Drug",
        "@id" : "https://www.pharmgkb.org/data/drug/PA450947",
        "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
        "id" : "PA450947",
        "name" : "phenytoin"
      },
      "groups" : [ {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      } ],
      "location" : {
        "id" : 1184754182,
        "copyNumber" : "1",
        "diplotypes" : [ {
          "id" : 1184754183,
          "allele1" : "*15:02:01"
        } ],
        "displayName" : "HLA-B *15:02:01",
        "genes" : [ {
          "objCls" : "Gene",
          "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
          "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
          "id" : "PA35056",
          "symbol" : "HLA-B",
          "name" : "major histocompatibility complex, class I, B"
        } ],
        "gpPosition" : -1,
        "haplotypes" : [ {
          "objCls" : "Haplotype",
          "@id" : "https://www.pharmgkb.org/data/haplotype/PA165954769",
          "@context" : "https://www.pharmgkb.org/jsonld/haplotype.jsonld",
          "id" : "PA165954769",
          "name" : "*15:02:01"
        } ],
        "refSeqPosition" : -1,
        "tagGene" : false,
        "type" : "haplotype"
      },
      "strength" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501929,
        "src" : "guidelineStrength",
        "term" : "N/A",
        "termId" : "guidelineStrength:981501929"
      },
      "textHtml" : "<p>Heterozygous variant. HLA-B*15:02 carrier; often reported as \"positive\" on a genotyping test.</p>"
    }, {
      "id" : 1184754171,
      "diplotypeIds1" : [ "PA165954769" ],
      "diplotypeIds2" : [ "PA165954769" ],
      "drug" : {
        "objCls" : "Drug",
        "@id" : "https://www.pharmgkb.org/data/drug/PA450947",
        "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
        "id" : "PA450947",
        "name" : "phenytoin"
      },
      "groups" : [ {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      } ],
      "location" : {
        "id" : 1184754341,
        "copyNumber" : "1",
        "diplotypes" : [ {
          "id" : 1184754342,
          "allele1" : "*15:02:01",
          "allele2" : "*15:02:01"
        } ],
        "displayName" : "HLA-B *15:02:01",
        "genes" : [ {
          "objCls" : "Gene",
          "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
          "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
          "id" : "PA35056",
          "symbol" : "HLA-B",
          "name" : "major histocompatibility complex, class I, B"
        } ],
        "gpPosition" : -1,
        "haplotypes" : [ {
          "objCls" : "Haplotype",
          "@id" : "https://www.pharmgkb.org/data/haplotype/PA165954769",
          "@context" : "https://www.pharmgkb.org/jsonld/haplotype.jsonld",
          "id" : "PA165954769",
          "name" : "*15:02:01"
        } ],
        "refSeqPosition" : -1,
        "tagGene" : false,
        "type" : "haplotype"
      },
      "strength" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501929,
        "src" : "guidelineStrength",
        "term" : "N/A",
        "termId" : "guidelineStrength:981501929"
      },
      "textHtml" : "<p>Homozygous variant.  <em>HLA-B*15:02</em> carrier; often reported as \"positive\" on a genotyping test.</p>"
    }, {
      "id" : 1184754187,
      "diplotypeIds1" : [ "PA165954769" ],
      "diplotypeIds2" : [ null ],
      "drug" : {
        "objCls" : "Drug",
        "@id" : "https://www.pharmgkb.org/data/drug/PA450947",
        "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
        "id" : "PA450947",
        "name" : "phenytoin"
      },
      "groups" : [ {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      } ],
      "location" : {
        "id" : 1184754185,
        "copyNumber" : "1",
        "diplotypes" : [ {
          "id" : 1184754186,
          "allele1" : "*15:02:01"
        } ],
        "displayName" : "HLA-B *15:02:01",
        "genes" : [ {
          "objCls" : "Gene",
          "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
          "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
          "id" : "PA35056",
          "symbol" : "HLA-B",
          "name" : "major histocompatibility complex, class I, B"
        } ],
        "gpPosition" : -1,
        "haplotypes" : [ {
          "objCls" : "Haplotype",
          "@id" : "https://www.pharmgkb.org/data/haplotype/PA165954769",
          "@context" : "https://www.pharmgkb.org/jsonld/haplotype.jsonld",
          "id" : "PA165954769",
          "name" : "*15:02:01"
        } ],
        "refSeqPosition" : -1,
        "tagGene" : false,
        "type" : "haplotype"
      },
      "strength" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501929,
        "src" : "guidelineStrength",
        "term" : "N/A",
        "termId" : "guidelineStrength:981501929"
      },
      "textHtml" : "<p>Significantly increased risk of phenytoin-associated cutaneous adverse reactions.</p>"
    }, {
      "id" : 1184754174,
      "diplotypeIds1" : [ "PA165954769" ],
      "diplotypeIds2" : [ "PA165954769" ],
      "drug" : {
        "objCls" : "Drug",
        "@id" : "https://www.pharmgkb.org/data/drug/PA450947",
        "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
        "id" : "PA450947",
        "name" : "phenytoin"
      },
      "groups" : [ {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      } ],
      "location" : {
        "id" : 1184754343,
        "copyNumber" : "1",
        "diplotypes" : [ {
          "id" : 1184754344,
          "allele1" : "*15:02:01",
          "allele2" : "*15:02:01"
        } ],
        "displayName" : "HLA-B *15:02:01",
        "genes" : [ {
          "objCls" : "Gene",
          "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
          "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
          "id" : "PA35056",
          "symbol" : "HLA-B",
          "name" : "major histocompatibility complex, class I, B"
        } ],
        "gpPosition" : -1,
        "haplotypes" : [ {
          "objCls" : "Haplotype",
          "@id" : "https://www.pharmgkb.org/data/haplotype/PA165954769",
          "@context" : "https://www.pharmgkb.org/jsonld/haplotype.jsonld",
          "id" : "PA165954769",
          "name" : "*15:02:01"
        } ],
        "refSeqPosition" : -1,
        "tagGene" : false,
        "type" : "haplotype"
      },
      "strength" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501929,
        "src" : "guidelineStrength",
        "term" : "N/A",
        "termId" : "guidelineStrength:981501929"
      },
      "textHtml" : "<p>Significantly increased risk of phenytoin-associated cutaneous adverse reactions.</p>"
    }, {
      "id" : 1184754188,
      "diplotypeIds1" : [ "PA165954769" ],
      "diplotypeIds2" : [ null ],
      "drug" : {
        "objCls" : "Drug",
        "@id" : "https://www.pharmgkb.org/data/drug/PA450947",
        "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
        "id" : "PA450947",
        "name" : "phenytoin"
      },
      "groups" : [ {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      } ],
      "location" : {
        "id" : 1184754189,
        "copyNumber" : "1",
        "diplotypes" : [ {
          "id" : 1184754190,
          "allele1" : "*15:02:01"
        } ],
        "displayName" : "HLA-B *15:02:01",
        "genes" : [ {
          "objCls" : "Gene",
          "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
          "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
          "id" : "PA35056",
          "symbol" : "HLA-B",
          "name" : "major histocompatibility complex, class I, B"
        } ],
        "gpPosition" : -1,
        "haplotypes" : [ {
          "objCls" : "Haplotype",
          "@id" : "https://www.pharmgkb.org/data/haplotype/PA165954769",
          "@context" : "https://www.pharmgkb.org/jsonld/haplotype.jsonld",
          "id" : "PA165954769",
          "name" : "*15:02:01"
        } ],
        "refSeqPosition" : -1,
        "tagGene" : false,
        "type" : "haplotype"
      },
      "strength" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501930,
        "src" : "guidelineStrength",
        "term" : "Strong",
        "termId" : "guidelineStrength:981501930"
      },
      "textHtml" : "<p>If patient is phenytoin- naive, do not use phenytoin/fosphenytoin. Note that carbamazepine should not be used as an alternative. Alternative medications such as oxcarbazepine, eslicarbazepine acetate and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele and caution should be used in choosing an alternative.</p>"
    }, {
      "id" : 1184754181,
      "diplotypeIds1" : [ "PA165954769" ],
      "diplotypeIds2" : [ "PA165954769" ],
      "drug" : {
        "objCls" : "Drug",
        "@id" : "https://www.pharmgkb.org/data/drug/PA450947",
        "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
        "id" : "PA450947",
        "name" : "phenytoin"
      },
      "groups" : [ {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      } ],
      "location" : {
        "id" : 1184754345,
        "copyNumber" : "1",
        "diplotypes" : [ {
          "id" : 1184754346,
          "allele1" : "*15:02:01",
          "allele2" : "*15:02:01"
        } ],
        "displayName" : "HLA-B *15:02:01",
        "genes" : [ {
          "objCls" : "Gene",
          "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
          "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
          "id" : "PA35056",
          "symbol" : "HLA-B",
          "name" : "major histocompatibility complex, class I, B"
        } ],
        "gpPosition" : -1,
        "haplotypes" : [ {
          "objCls" : "Haplotype",
          "@id" : "https://www.pharmgkb.org/data/haplotype/PA165954769",
          "@context" : "https://www.pharmgkb.org/jsonld/haplotype.jsonld",
          "id" : "PA165954769",
          "name" : "*15:02:01"
        } ],
        "refSeqPosition" : -1,
        "tagGene" : false,
        "type" : "haplotype"
      },
      "strength" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501930,
        "src" : "guidelineStrength",
        "term" : "Strong",
        "termId" : "guidelineStrength:981501930"
      },
      "textHtml" : "<p>If patient is phenytoin- naive, do not use phenytoin/fosphenytoin. Note that carbamazepine should not be used as an alternative.  Alternative medications such as oxcarbazepine, eslicarbazepine acetate and lamotrigine have some evidence linking SJS/TEN with the <em>HLA-B*15:02</em> allele and caution should be used in choosing an alternative.</p>"
    } ]
  } ],
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA450947",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA450947",
    "name" : "phenytoin"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA126",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA126",
    "symbol" : "CYP2C9",
    "name" : "cytochrome P450, family 2, subfamily C, polypeptide 9"
  }, {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA35056",
    "symbol" : "HLA-B",
    "name" : "major histocompatibility complex, class I, B"
  } ],
  "source" : "CPIC",
  "summaryHtml" : "<p>Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (\"HLA-B*15:02-positive\") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype may require reduced doses of phenytoin.</p>",
  "textHtml" : "<h3 id=\"August2014\">August 2014</h3><p><em>Accepted article preview online August 2014; Advance online publication September 2014</em></p><ul><li>Guidelines regarding the use of pharmacogenomic tests in dosing for phenytoin have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (<a href=\"/contributors/consortia/cpic_profile.jsp\">CPIC</a>).</li><li>Excerpt from the 2014 phenytoin dosing guidelines:<ul><li>\"[A]t least a 25% reduction of the recommended starting maintenance dose may be considered for CYP2C9 intermediate metabolizers with subsequent maintenance doses adjusted based on therapeutic drug monitoring and response. For CYP2C9 poor metabolizers, consider at least a 50% reduction of starting maintenance dose with subsequent maintenance doses adjusted based on therapeutic drug monitoring or response.\"</li><li>\"[R]egardless of the CYP2C9 genotype and individual's ancestry or age, if the HLA-B*15:02 test result is positive, the recommendation is to consider using an anticonvulsant other than carbamazepine and phenytoin unless the benefits of treating the underlying disease clearly outweigh the risks... Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele and thus caution should be used in choosing alternatives to phenytoin.\"</li></ul></li><li>Download and read:<ul><li><a href=\"/download.do?objCls=Attachment&amp;objId=Phenytoin_guideline_manuscript_revised_final_endnote.pdf\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for <em>CYP2C9</em> and <em>HLA-B</em> Genotype and Phenytoin Dosing</a> </li><li><a href=\"/download.do?objCls=Attachment&amp;objId=PhenytoinManuscript_Supplement_revised_final.pdf\">2014 supplement</a></li><li><a href=\"/download.do?objCls=Attachment&amp;objId=Phenytoin_translation_table_final.xlsx\">2014 phenytoin translation table</a></li></ul></li></ul><h3 id=\"Table1PhenytoinfosphenytointherapyrecommendationsbasedonHLABandCYP2C9phenotypegenotype\">Table 1: Phenytoin/fosphenytoin therapy recommendations based on <em>HLA-B</em> and <em>CYP2C9</em> phenotype/genotype</h3><p><em>Adapted from Tables 1 and 2 of the 2014 guideline manuscript.</em></p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><td> <strong>Phenotype/Genotype</strong> </td><td> <strong><em>HLA-B*15:02</em> carrier</strong> <br/><em>Genotype:</em> 1 or 2 *15:02 alleles; \"positive\" </td><td> <strong><em>HLA-B*15:02</em> non-carrier</strong> <br/><em>Genotype:</em> No HLA-B*15:02 alleles reported; \"negative\" </td></tr><tr><td> <strong>CYP2C9 Extensive Metabolizer</strong> <br/>normal activity ~91% of patients <br/><em>Genotype:</em> An individual carrying 2 normal activity alleles <br/><em>Example diplotype:</em> *1/*1 </td><td> <em>Implication:</em> Increased risk of phenytoin-induced SJS/TEN. <br/><strong><em>Therapeutic Recommendation:</em>  If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</strong> <br/><em>Strength of Recommendation: STRONG</em> </td><td> <em>Implication:</em> Normal phenytoin metabolism. <br/><strong><em>Therapeutic Recommendation:</em> Initiate therapy with recommended maintenance dose <sup>d</sup>.</strong> <br/><em>Strength of Recommendation: STRONG</em> </td></tr><tr><td> <strong>CYP2C9 Intermediate Metabolizer</strong> <br/>heterozygote ~8% of patients <br/><em>Genotype:</em>  An individual carrying one normal activity allele plus one decreased function allele <br/><em>Example diplotypes:</em> *1/*3, *1/*2 </td><td> <em>Implication:</em> Increased risk of phenytoin-induced SJS/TEN. <br/><strong><em>Therapeutic Recommendation:</em> If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</strong> <br/><em>Strength of Recommendation: STRONG</em> </td><td> <em>Implication:</em> Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities. <br/><strong><em>Therapeutic Recommendation:</em> Consider 25% reduction of recommended starting maintenance dose <sup>d</sup>.  Subsequent doses should be adjusted according to therapeutic drug monitoring and response.</strong> <br/><em>Strength of Recommendation: MODERATE</em> </td></tr><tr><td> <strong>CYP2C9 Poor Metabolizer</strong> <br/>homozygous variant ~1% of patients <br/><em>Genotype:</em> An individual carrying 2 decreased function alleles <br/><em>Example diplotypes:</em> *2/*2, *3/*3, *2/*3 </td><td> <em>Implication:</em> Increased risk of phenytoin-induced SJS/TEN. <br/><strong><em>Therapeutic Recommendation:</em> If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</strong> <br/><em>Strength of Recommendation: STRONG</em> </td><td> <em>Implication:</em> Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities. <br/><strong><em>Therapeutic Recommendation:</em> Consider 50% reduction of recommended starting maintenance dose <sup>d</sup>.  Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.</strong>  <br/><em>Strength of Recommendation: STRONG</em> </td></tr></table>"
}